Publicaciones en colaboración con investigadores/as de Hospital Clínico Universitario Lozano Blesa (14)

2023

  1. CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 8, pp. 1557-1568

2022

  1. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

    European Journal of Cancer, Vol. 168, pp. 12-24

2021

  1. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

    European Journal of Cancer, Vol. 156, pp. 70-82

  2. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

    Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499

2019

  1. Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

    Breast Cancer Research, Vol. 21, Núm. 1

  2. Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer

    European Journal of Cancer Care, Vol. 28, Núm. 6

  3. SEOM clinical guidelines in early stage breast cancer (2018)

    Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 18-30

  4. Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): An open-label, single-group, multicenter, phase 2 trial

    BMC Medicine, Vol. 17, Núm. 1

2018

  1. Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): An open-label, randomized, three-arm, multicenter, window-of-opportunity study

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii64

  2. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain

    Clinical and Translational Oncology, Vol. 20, Núm. 6, pp. 753-760

2016

  1. Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile

    Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428

2010

  1. Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: A multicenter phase II study (SOLTI 0301 trial)

    Annals of Oncology, Vol. 21, Núm. 7, pp. 1442-1447

  2. SEOM clinical guidelines for the treatment of early breast cancer

    Clinical and Translational Oncology, Vol. 12, Núm. 11, pp. 711-718

2006

  1. Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: Efficacy and correlation with HER2 extracellular domain

    Clinical and Translational Oncology, Vol. 8, Núm. 12, pp. 896-902